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Ovarian cancer and oral contraceptives: collaborative 
reanalysis of data from 45 epidemiological studies 
including 23 257 women with ovarian cancer and 
87 303 controls
Collaborative Group on Epidemiological Studies of Ovarian Cancer*
Summary
Background Oral contraceptives were introduced almost 50 years ago, and over 100 million women currently use 
them. Oral contraceptives can reduce the risk of ovarian cancer, but the eventual public-health eﬀ ects of this reduction 
will depend on how long the protection lasts after use ceases. We aimed to assess these eﬀ ects.
Methods Individual data for 23 257 women with ovarian cancer (cases) and 87 303 without ovarian cancer (controls) 
from 45 epidemiological studies in 21 countries were checked and analysed centrally. The relative risk of ovarian 
cancer in relation to oral contraceptive use was estimated, stratifying by study, age, parity, and hysterectomy.
Findings Overall 7308 (31%) cases and 32 717 (37%) controls had ever used oral contraceptives, for average durations 
among users of 4·4 and 5·0 years, respectively. The median year of cancer diagnosis was 1993, when cases were aged 
an average of 56 years. The longer that women had used oral contraceptives, the greater the reduction in ovarian 
cancer risk (p<0·0001). This reduction in risk persisted for more than 30 years after oral contraceptive use had ceased 
but became somewhat attenuated over time—the proportional risk reductions per 5 years of use were 29% 
(95% CI 23–34%) for use that had ceased less than 10 years previously, 19% (14–24%) for use that had ceased 
10–19 years previously, and 15% (9–21%) for use that had ceased 20–29 years previously. Use during the 1960s, 1970s, 
and 1980s was associated with similar proportional risk reductions, although typical oestrogen doses in the 1960s 
were more than double those in the 1980s. The incidence of mucinous tumours (12% of the total) seemed little 
aﬀ ected by oral contraceptives, but otherwise the proportional risk reduction did not vary much between diﬀ erent 
histological types. In high-income countries, 10 years use of oral contraceptives was estimated to reduce ovarian 
cancer incidence before age 75 from 1·2 to 0·8 per 100 users and mortality from 0·7 to 0·5 per 100; for every 
5000 woman-years of use, about two ovarian cancers and one death from the disease before age 75 are prevented.
Interpretation Use of oral contraceptives confers long-term protection against ovarian cancer. These ﬁ ndings suggest 
that oral contraceptives have already prevented some 200 000 ovarian cancers and 100 000 deaths from the disease, 
and that over the next few decades the number of cancers prevented will rise to at least 30 000 per year.
Introduction
Use of oral contraceptives has long been known to reduce 
the incidence of ovarian cancer.1,2 Because ovarian cancer 
is not common in young women and the incidence 
increases with age, the public-health eﬀ ect of this 
reduction depends mainly on how much the reduced risk 
persists decades after oral contraceptive use ceases. To 
investigate the relation between use of oral contraceptives 
and the subsequent risk of ovarian cancer, data for 
individual women from 45 epidemiological studies of 
ovarian cancer1–47 have been brought together, checked, 
and analysed centrally.
Methods
Identiﬁ cation of studies and collection of data
Epidemiological studies were eligible for this 
collaboration if they included at least 100 women with 
ovarian cancer (40 cases in cohort studies) and recorded 
information on each woman’s reproductive history and 
use of oral contraceptives. Studies were identiﬁ ed from 
review articles, from computer-aided literature reviews 
up to January 2006, using Medline, Embase, and 
PubMed, and from discussions with colleagues. 
Principal investigators from each eligible study were 
invited to participate. Of the 48 eligible studies 
identiﬁ ed1–50 (including one multicentre international 
study25,31,36) all but three48–50 contributed to the collab-
oration. Individual data could not be retrieved by the 
investigators from two of these three studies48,49 and 
investigators for the third50 could not be located.
Cases were deﬁ ned as women with malignant 
epithelial or non-epithelial ovarian cancer and controls 
were women without ovarian cancer who had not 
undergone bilateral oophorectomy. Data for individual 
women were sought from principal investigators of 
every study on socio-demographic factors, reproductive 
and menstrual history, use of hormonal contraceptives, 
use of hormonal therapies for the menopause, height, 
weight, family history of breast and ovarian cancer, and 
consumption of alcohol and tobacco. Cohort studies 
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were incorporated using a nested case-control design, in 
which up to four controls were selected at random, 
matched for follow-up duration, age of the case at 
diagnosis, and, where appropriate, by broad geographical 
region. Data provided by investigators were checked and 
collated centrally so that analyses could be done using 
deﬁ nitions as similar across studies as was possible. 
Apparent inconsistencies in the data were rectiﬁ ed, 
where possible, by correspondence with the investigators. 
After the records had been checked and corrected, 
investigators were sent summary tables and listings of 
the variables to be used in analyses for ﬁ nal 
conﬁ rmation.
Information on the histological classiﬁ cation of the 
ovarian cancers had been collected by principal 
investigators of all but 12 of the 45 participating 
studies.1,5,6,10,12,15,16,21,22,26,30,45 The classiﬁ cation system adopted 
in each study was used centrally to categorise tumours 
as epithelial or non-epithelial and, among the epithelial 
tumours, to categorise them further as clear cell, 
endometrioid, mucinous, serous, mixed, or other, 
according to the 10th revision of the International 
Country Number of 
cases/controls
Median year of 
diagnosis
Mean age of 
cases (years)
Percent ever-used oral 
contraceptives (cases/controls)
Prospective studies
13 prospective studies
Oxford/FPA22 UK 49/196 1988 48·1 27/67
BCCDS40 USA 365/1399 1989 65·3 20/23
Nurses’ Health Study19 USA 680/2720 1991 58·7 39/42
RCGP26 UK 176/704 1991 52·8 49/60
Radiation Technologists45 USA 41/171 1992 48·2 71/75
Netherlands Cohort46 Netherlands 253/1777 1992 67·9 14/24
CPS-II Mortality21 USA 2597/10976 1994 70·2 17/21
CPS-II Nutrition47 USA 350/1405 1997 67·8 30/36
Southern Sweden38 Sweden 73/288 1997 57·4 38/50
EPIC
Spain25 Spain 33/131 1997 52·9 33/39
Netherlands30 Netherlands 35/140 1999 61·4 54/64
Oxford36 UK 55/217 2000 58·7 64/57
WLH41 Norway/Sweden 99/399 1998 49·3 81/85
NOWAC39 Norway 105/420 2000 59·8 25/33
Million Women Study27 UK 2815/11258 2001 60·2 48/56
All prospective studies 6 countries 7726/32201 1998 63·7 34/39
Case-control studies
19 case-control studies, with population controls
Casagrande/Pike2 USA 150/150 1974 40·2 43/40
Weiss5 USA 319/751 1976 54·8 15/27
Nasca7 USA 403/714 1978 54·8 19/21
Cramer6 USA 248/238 1979 51·5 17/23
CASH8 USA 573/4228 1981 41·9 52/64
Whittemore9 USA 215/646 1984 50·8 47/56
Shu/Brinton13 China 229/229 1985 48·4 13/7
Western New York37 USA 123/696 1988 58·6 17/30
Risch17 Canada 450/564 1991 56·7 39/50
Green/Purdie20 Australia 793/855 1992 55·2 49/64
Mosgaard24 Denmark 915/1099 1992 46·0 65/77
Cramer II28 USA 564/525 1993 51·2 45/55
Riman34 Sweden 808/3897 1994 61·5 28/29
German OCS35 Germany 282/533 1995 55·2 34/51
Pike/Wu42 USA 477/660 1995 55·5 54/63
Goodman/Wu33 USA 720/892 1996 55·0 39/54
NISOC Study32 Israel 1351/2264 1996 56·6 20/23
OVCARE43 USA 320/1412 1996 45·5 79/88
SHARE29 USA 767/1367 1996 51·6 47/62
(Continues on next page)
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Classiﬁ cation of Diseases (ICD10).51 Whenever possible 
epithelial tumours were further categorised as to whether 
they were borderline malignant or fully malignant.51
Deﬁ ning oral contraceptive use
Principal investigators of every participating study had 
collected information on whether individual women 
had ever used oral contraceptives, and most had also 
collected information on total duration of use, age at 
ﬁ rst and last use, and calendar year of ﬁ rst and last use. 
The cases had been diagnosed with ovarian cancer on 
average about 20 years after they had ﬁ rst used oral 
contraceptives. Validation studies have shown that, 
although women were able to recall whether or not they 
took oral contraceptives in the past, their ability to recall 
reliably which preparations they used declined soon 
after use ceased.52 There is, however, a strong relation 
between calendar year of use and the dose of oestrogen 
in the oral contraceptives typically used.29,53,54 In the USA 
and UK, for example, the oral contraceptives prescribed 
before 1970 were typically high-dose preparations, often 
containing 100 μg or more of oestrogen; between 1970 
and 1980 prescriptions were typically for medium-dose 
preparations containing about 50 μg of oestrogen; and 
by 1980 most prescriptions were for low-dose 
preparations, containing 30 μg or less of oestrogen.53,54 
Calendar year of oral contraceptive use could therefore 
be taken, at least roughly, to be a proxy for oestrogen 
dose and women were classiﬁ ed according to the 
mid-year of use (before 1970, 1970–79, and 1980 or after) 
to correspond to likely use of high-dose, medium-dose, 
and low-dose preparations. Sensitivity analyses were 
done, also classifying women by the calendar year of 
ﬁ rst and last use. Although most studies did not 
distinguish between oral contraceptives containing 
oestrogen-progestagen combinations and preparations 
containing progestagens only, more than 95% of oral 
contraceptives used in these populations would have 
been of the combined type.55
Statistical analysis and presentation of results
The statistical methods were similar to those used when 
analysing the worldwide data for the eﬀ ects of oral 
contraceptives on breast cancer.55 Data from diﬀ erent 
studies were combined by means of the Mantel-Haenszel 
stratiﬁ cation technique, the stratum-speciﬁ c quantities 
calculated being the standard “observed minus 
expected” (O–E) numbers of women with ovarian 
cancer, together with their variances and covariances.55–57 
Use of these simple stratiﬁ ed O–E values has the 
advantage of avoiding assumptions about the precise 
forms of any relations in the data. The stratiﬁ ed O–E 
values, together with their variances and covariances, 
yield both odds ratios (subsequently referred to as 
relative risks) and associated p values. When two groups 
only are compared, relative risk estimates are obtained 
from the O–E value and its variance (V) by the one-step 
method56,57 as are their standard errors (SE) and CIs. 
The actual formulae are: log relative risk=(O–E)/V; and 
its variance=1/V. When more than two groups are 
compared, variances are estimated by treating the 
relative risks as ﬂ oating absolute risks (FARs).58 This 
(Continued from previous page)
13 case-control studies, with hospital controls
Newhouse1 UK 289/582 1973 54·1 7/11
McGowan3 USA 196/197 1975 49·9 21/28
Paﬀ enbarger10 USA 111/481 1975 55·4 23/21
Hildreth/Kelsey4 USA 62/1068 1978 60·1 5/11
Hartge12 USA 296/334 1979 54·4 25/23
Booth11 UK 233/441 1980 51·5 16/26
WHO
Developed14 Australia, GDR, Israel 202/3862 1982 41·4 29/48
Developing14 8 countries* 431/14869 1983 39·3 22/34
Rosenberg18 USA 960/3828 1983 49·6 15/19
Negri/Franceschi15 Italy 976/2494 1986 53·1 7/10
PEDS23 USA 411/1718 1989 54·6 33/32
Tzonou/Tricopoulos16 Greece 339/447 1990 56·2 2/6
Negri31 Italy 1031/2411 1995 54·9 11/11
Zhejiang-Curtin44 China 287/650 1999 46·3 24/36
All case-control studies 18 countries 15 531/55 102 1992 52·4 30/37
Total
All 45 studies 21 countries 23 257/87 303 1993 56·1 31/37
*Chile, China, Columbia, Kenya, Mexico, Nigeria, Philippines, Thailand.
Table 1: Details of studies and women included
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approach yields ﬂ oated standard errors (FSE) and 
ﬂ oated conﬁ dence intervals (FCI). The use of ﬂ oating 
absolute risks rather than conventional methods does 
not alter the relative risks but slightly reduces the 
variances attributed to the relative risks that are not 
deﬁ ned as 1·0. This method enables valid comparisons 
between any two exposure groups, even if neither is the 
baseline group. Any comparison between two log 
relative risks must, however, take the variation in each 
estimate into account (by summing their variances, as 
described elsewhere55). Because of the large number of 
relative risk estimates presented, 99% CIs are generally 
used in the ﬁ gures; however, summary results in the 
text and ﬁ gures use 95% CIs.
To ensure that women in one study were compared 
directly only with similar women in the same study, all 
analyses were routinely stratiﬁ ed by study, by centre 
within study, by ﬁ ne divisions of age (single years of 
age from 16 to 69, then 70–74, 75–79, 80–84, and 85–89), 
parity (0, 1, 2, 3, 4, 5, 6+; not known) and hysterectomy 
status (yes, no, unknown). These stratiﬁ cation variables 
were selected because they are related both to the use of 
oral contraceptives and to the risk of developing ovarian 
cancer. The eﬀ ect on the main ﬁ ndings of 12 other 
potential confounding factors (ethnic group, education, 
age at ﬁ rst birth, family history of breast cancer, age at 
menarche, menopausal status, use of hormone 
replacement therapy, height, weight, body-mass index, 
alcohol use, and smoking) was examined by comparing 
results before and after stratiﬁ cation for each variable 
separately and all simultaneously.
When results in the ﬁ gures are represented by squares 
and lines the position of the square indicates the value of 
the relative risk (its area is inversely proportional to the 
variance of the logarithm of the relative risk, thereby 
providing an indication of the amount of statistical 
13 prospective studies:
BCCDS (USA) 72/323 293/1076 4·0/3·9 9·5 (18·5)
Nurses' Health Study (USA) 267/1152 413/1568 3·7/4·4 20·6 (10·1)
RCGP (UK) 86/422 90/282 5·5/5·9 10·9 (16·2)
Netherlands Cohort (Netherlands) 35/434 218/1343 7·1/7·8 9·6 (17·0)
CPS-II Mortality (USA) 437/2330 2160/8646 4·5/5·6 19·0 (5·9)
CPS-II Nutrition (USA) 105/508 245/897 5·0/5·3 –2·7 (12·4)
Million Women Study (UK) 1350/6245 1465/5013 5·7/6·9 16·2 (3·2)
Other 241/1147 249/815 5·3/6·1 21·3 (11·2)
All prospective studies                 2593/12 561 5133/19 640 5·2/6·2 16·2 (2·5)
19 case–control studies, with population controls:
Nasca (USA) 78/149 325/565 2·3/3·3 45·5 (26·8)
CASH (USA) 299/2688 274/1540 3·1/4·4 31·6 (8·0)
Risch (Canada) 174/280 276/284 4·2/5·5 13·2 (14·0)
Green/Purdie (Australia) 392/551 401/304 5·3/7·2 36·9 (8·4)
Mosgaard (Denmark) 592/851 323/248 3·4/4·0 31·2 (11·0)
Cramer (USA) 292/342 520/421 3·9/5·1 31·4 (12·5)
Riman (Sweden) 223/1143 585/2754 4·1/5·4 24·3 (8·0)
German OCS (Germany) 96/270 186/263 8·2/9·5 18·2 (17·0)
Pike/Wu (USA) 255/415 222/245 4·3/5·5 24·0 (10·9)
Goodman/Wu (USA) 282/483 438/409 4·2/5·3 31·1 (14·2)
NISOC Study (Israel) 272/519 1079/1745 5·6/5·8 –5·9 (10·1)
OVCARE (USA) 254/1238 66/174 5·1/6·2 20·7 (9·8)
SHARE (USA) 362/850 405/517 4·1/4·9 21·1 (9·0)
Other 264/850 772/1622 3·0/4·1 37·7 (13·9)
All case-control, population controls          3835/10 629 5872/11091 4·2/5·2 25·6 (2·8)
13 case-control studies, with hospital controls:
WHO-developed countries 59/1870 143/1992 2·3/4·4 26·6 (27·0)
WHO-developing countries 96/5093 335/9776 2·4/2·6 7·7 (17·5)
Rosenberg (USA) 141/717 819/3111 3·7/4·6 38·9 (13·7)
Negri/Franceschi (Italy) 174/520 1833/4385 2·5/3·5 42·9 (17·8)
Zhejiang–Curtin (China) 68/234 219/416 2·5/2·9 –1·1 (22·1)
Other 342/1093 1595/4175 3·2/3·8 –10·2 (23·9)
All case-control, hospital controls     880/9527 4944/23 855 2·9/3·3 24·7 (7·6)
All studies                             7308/32 717 15949/54 586 4·4/5·0 20·3 (1·8)
0 0·5 1·0 1·5 2·0 –100% –50%   0%  50% 100%
RR (SE) RR (99% CI)
Oral contraceptive use
Ever Never
Cases/controls Cases/controls
Relative risk* of ovarian
cancer in ever vs never users
Average duration
of oral contraceptive
use (years, in users)
Cases/controls % (99% CI)% (SE)
Users only: percent reduction in risk* of ovarian
cancer per 5 years of oral contraceptive use
0·72 (0·15)
0·88 (0·10)
0·68 (0·17)
0·62 (0·15)
0·72 (0·05)
0·83 (0·13)
0·74 (0·04)
0·55 (0·11)
0·74 (0·03)
0·95 (0·21)
0·63 (0·08)
0·50 (0·13)
0·49 (0·10)
0·60 (0·09)
0·80 (0·14)
0·79 (0·09)
0·63 (0·18)
0·78 (0·15)
0·58 (0·14)
0·82 (0·09)
0·54 (0·16)
0·64 (0·09)
0·85 (0·13)
0·69 (0·03)
0·76 (0·16)
0·70 (0·12)
0·76 (0·11)
0·94 (0·12)
0·72 (0·16)
0·87 (0·11)
0·81 (0·05)
0·73 (0·02)
Figure 1: Details of and results from studies contributing data for oral contraceptive use and ovarian cancer
Dotted lines represent overall result for all women. *Stratiﬁ ed by study, age, parity, and hysterectomy. 
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information available for that particular estimate) and the 
length of the line represents the CI. When appropriate, a 
trend in the relative risk of ovarian cancer with increasing 
duration of oral contraceptive use was calculated only 
among users (ie, relative risks for ever users were com-
pared with each other). For these calculations and for the 
graphical presentation of such results, the duration of 
oral contra ceptive use associated with a particular category 
was taken to be the median duration within that category.
To estimate the absolute risk of ovarian cancer 
associated with 5, 10, and 15 years use of oral 
contraceptives, the relative risks obtained here were 
applied to published data for the age-speciﬁ c incidence 
and mortality rates for ovarian cancer in high income 
countries.59,60 The age-speciﬁ c rates were then used to 
estimate cumulative rates up to age 75. To illustrate the 
public-health eﬀ ect of oral contraceptives on ovarian 
cancer, the numbers of cancers prevented in each of the 
ﬁ ve decades, starting with the 1960s, were estimated by 
applying the relative risks found here and statistics on 
oral contraceptive use in diﬀ erent generations of women 
to age-speciﬁ c ovarian cancer incidence and mortality 
rates. In high-income countries the estimated proportions 
of ever-users of oral contraceptives in each successive 
5-year birth cohort from 1916–20 to 1951–55 were: 5%, 15%, 
29%, 40%, 51%, 65%, 76%, and 80%, respectively, with 
the average years of use among them being 3·6, 4·5, 5·1, 
5·5, 5·8, 6·1, 6·3, and 6·3, respectively. These estimates 
were based on the pattern of oral contraceptive use 
recorded among controls in this collaboration and in a 
previous international collaboration;55 for women born 
after 1955 use was assumed to be the same as for 
the 1951–55 birth cohort. In middle-income and 
low-income countries, oral contraceptive use was 
uncommon until recently.61,62
Role of the funding source
The sponsors of the study had no role in the study design, 
data collection, data analysis, data interpretation or 
writing of the report. The writing committee had full 
access to all the data and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
Details of the 45 participating studies are shown in 
table 1. The studies are listed according to their design 
and, within each type of design, by the median year when 
the ovarian cancers were diagnosed in each study. 
Altogether the 45 studies were done in 21 countries, 
mostly in Europe or the USA, and they contributed a total 
of 23 257 women with ovarian cancer (cases) and 
87 303 women without ovarian cancer (controls) to the 
analyses. The cancers were diagnosed in 1993, on average, 
and the mean age at diagnosis was 56 years; 7% were 
aged younger than 35 years, 11% were aged 35–44 years, 
25% were aged 45–54 years, 30% were aged 55–64 years, 
and 27% were older.
Overall, 31% (7308) of the women with ovarian cancer 
and 37% (32 717) of the controls had used oral 
contraceptives, and the average duration of use was 4·4 
and 5·0 years, respectively. Figure 1 shows the 
study-speciﬁ c and combined relative risks of ovarian 
cancer in ever-users compared with never-users of oral 
contraceptives. (Studies with information content [var 
(O–E)] less than 20 are included in the “other” category 
for the relevant study design.) For each of the three types 
of study design there was a highly signiﬁ cant reduction 
in the relative risk of ovarian cancer in ever users of oral 
contraceptives. Overall, for ever vs never users the overall 
relative risk is 0·73, 95% CI 0·70–0·76, p<0·0001.
The longer that women had used oral contraceptives, 
the lower their risk of ovarian cancer (table 2). The 
overall relative risk decreased by 20% (95% CI, 18–23%, 
p<0·0001) for each 5 years of use (ie, it was multiplied 
by a factor of 0·8). In women who had used oral 
Duration of oral 
contraceptive use (mean)
Cases/controls RR and 99% FCI*
Never 14703/51908 1·00 (0·96–1·04)
Less than 1 year (0·4 years) 1492/6353 1·00 (0·91–1·10)
1–4 years (2·4 years) 2686/11329 0·78 (0·73–0·83)
5–9 years (6·8 years ) 1562/7118 0·64 (0·59–0·69)
10–14 years (11·6 years) 655/3765 0·56 (0·50–0·62)
15 years or more (18·3 years) 247/1639 0·42 (0·36–0·49)
Numbers do not always add to the total, because of missing values. *Relative 
risks (RR) stratiﬁ ed by study, age, parity, and hysterectomy. Test for trend with 
duration of use, p<0·00001.
Table 2: Relative risk of ovarian cancer in users of oral contraceptives 
compared with never users, by duration of oral contraceptive use
Never use
 0
 0
 5 10 15
Duration of use of oral contraceptives (years)
0·3
0·4
0·5
0·6
0·7
0·8
0·9
1·0
1·1
Re
la
tiv
e 
ris
k 
(9
5%
 F
CI
)
20
0·1
0·2
Figure 2: Relative risk* of ovarian cancer by duration of use of oral contraceptives
*Stratiﬁ ed by study, age, parity, and hysterectomy.
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contraceptives for about 15 years the risk of ovarian 
cancer was halved (ﬁ gure 2). The eﬀ ect of various 
potential confounding factors on the relation shown in 
ﬁ gure 2 was examined by adjusting in turn for ethnic 
group, education, age at ﬁ rst birth, family history of 
breast cancer, age at menarche, menopausal status, use 
of hormone replacement therapy, height, weight, 
body-mass index, alcohol use, and tobacco consumption 
and also by adjusting for all the factors simultaneously. 
All these additional adjustments altered the estimated 
20% decrease in relative risk per 5 years use by less 
than 1%.
The women with ovarian cancer had stopped use of 
oral contraceptives an average of 18·6 years previously, 
and table 3 shows results by time since ceasing use. The 
relative risks for ovarian cancer were lower the more 
recently women had used oral contraceptives. The 
average duration of use was, however, greater in recent 
users than in those who had stopped a long time 
previously (table 3). When the relation with duration of 
use was examined within categories of recency of use, 
there was some wearing oﬀ  of the eﬀ ect of oral 
contraceptives the longer ago use had ceased: the 
proportional declines in relative risk per 5 years use of 
oral contraceptives were 29% for those whose use had 
ceased less than 10 years previously, 19% for use ceased 
10–19 years previously, and 15% for use ceased 20–29 years 
previously (test for heterogeneity, p=0·004, ﬁ gure 3). 
These ﬁ ndings are unlikely to indicate misclassiﬁ cation 
of use long ago, since women recall reliably whether or 
not they took oral contraceptives in the past (but cannot 
recall the type used).52 Despite this attenuation in 
proportional (but not in absolute) risk reduction after 
stopping use, the risk of ovarian cancer was still 
Ever-users* Duration of use of oral contraceptives Percent decline in the risk for 
every 5 years use (95% CI), 
comparing ever-users
<5 years 5–9 years 10+ years
Current use or use less than 10 years previously
Relative risk (99% FCI) 0·57 (0·50–0·64)† 0·88 (0·75–1·04) 0·52 (0·43–0·64) 0·39 (0·33–0·47) 28·9 (23·0–34·3)
Cases/controls 1137/8911 636/4779 269/2268 232/1864
Mean duration of use 5·8 years 1·7 years 7·2 years 14·7 years
Last use 10–19 years previously
Relative risk (99% FCI) 0·67 (0·62–0·73) 0·85 (0·75–0·97) 0·62 (0·53–0·73) 0·51 (0·44–0·59) 19·4 (14·2–24·2)
Cases/controls 1626/8153 844/4559 419/1716 363/1878
Mean duration of use 5·6 years 1·6 years 6·9 years 13·8 years
Last use 20–29 years previously
Relative risk (99% FCI) 0·76 (0·71–0·81) 0·81 (0·74–0·89) 0·69 (0·60–0·78) 0·60 (0·51–0·72) 15·1 (8·5–21·2)
Cases/controls 2202/8146 1425/4621 528/2141 249/1384
Mean duration of use 4·6 years 1·8 years 6·7 years 11·8 years
Last use 30 or more years previously
Relative risk (99% FCI) 0·86 (0·76–0·97) 0·83 (0·73–0·95) Insuﬃ  cient data Insuﬃ  cient data Insuﬃ  cient data
Cases/controls 697/2617 584/2161
Mean duration of use 2·5 years 1·5 years
*Never users include 14 703 cases and 51 908 controls with relative risk of 1·00 (99% FCI 0·96–1·04). All relative risks are stratiﬁ ed by study, age, parity, and hysterectomy. 
Numbers do not always add to the total, because of missing values. †For current use and use that ceased less than 2 years previously, relative risk was 0·59 (99% FCI 0·50–0·70).
Table 3: Relative risk of ovarian cancer in ever-users of oral contraceptives compared with that in never users, by time since last use and duration of use of 
oral contraceptives*
Never use
 0  5 10
Duration of use of oral contraceptives (years)
0·3
0·4
0·5
0·6
0·7
0·8
0·9
1·0
1·1
Re
la
tiv
e 
ris
k 
(9
5%
 F
CI
)
20–29 years since last use
10–19 years since last use
<10 years since last use
 0
0·1
0·2
Figure 3: Relative risk* of ovarian cancer by duration and time since last use of oral contraceptives
*Stratiﬁ ed by study, age, parity, and hysterectomy.
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signiﬁ cantly reduced 30 or more years after use had 
ceased (table 3).
Once duration of use and time since last use of oral 
contraceptives were taken into account, no other index 
of the timing of use—eg, women’s ages at ﬁ rst and last 
use, and use before and after the birth of a child—had 
any material further eﬀ ect on the relative risk of ovarian 
cancer. Table 4 shows results according to the women’s 
ages at ﬁ rst use of oral contraceptives. There was no 
signiﬁ cant heterogeneity in the decline in relative risk 
with increasing duration of oral contraceptive use 
across women who started use at diﬀ erent ages (test for 
heterogeneity, p=0·5). The distribution of women’s 
ages at ﬁ rst use was 16% for those younger than 
20 years, 34% for 20–24 years, 21% for 25–29 years, 
14% for 30–34 years, 8% for 35–39 years, and 7% for 
older ages. Women’s ages at last use were closely 
correlated with their age at ﬁ rst use, and the decline in 
ovarian cancer risk with increasing duration of use did 
not diﬀ er signiﬁ cantly by women’s age at last use 
(3% were younger than 20 years at last use, 18% were 
20–24, 24% were 25–29, 21% were 30–34, 15% were 
35–39, 11% were 40–44, and 8% were older). The decline 
in ovarian cancer risk with increasing duration of use 
did not vary signiﬁ cantly by whether women had begun 
using oral contraceptives before or after the birth of 
their ﬁ rst child (decreases in relative risk per 5 years of 
use 26% vs 18%; test for heterogeneity, p=0·1).
As described in the methods section, the oestrogen 
dose in oral contraceptive preparations typically used in 
the 1960s was more than double that of preparations 
typically used in the 1980s.29,53,54 Among women with 
ovarian cancer, almost 40% had a mid-year of oral 
Ever-users* Duration of use of oral contraceptives Percent decline in the risk for 
every 5 years use (95% CI), 
comparing ever-users
<5 years 5–9 years 10+ years
First use before age 20 years
Relative risk (99% FCI) 0·71 (0·63–0·81) 0·95 (0·80–1·13) 0·65 (0·53–0·81) 0·50 (0·40–0·64) 24·6 (17·0–31·6)
Cases/controls 1009/4381 509/2159 280/1135 169/841
Mean duration of use 5·4 years 1·9 years 7·0 years 14·2 years
First use at age 20–24 years
Relative risk (99% FCI) 0·69 (0·64–0·74) 0·81 (0·73–0·90) 0·68 (0·59–0·78) 0·50 (0·43–0·58) 19·6 (14·4–24·5)
Cases/controls 2051/9384 1166/5063 508/2241 328/1824
Mean duration of use 5·3 years 1·8 years 6·9 years 13·9 years
First use at age 25–29 years
Relative risk (99% FCI) 0·72 (0·66–0·79) 0·84 (0·75–0·95) 0·64 (0·53–0·78) 0·50 (0·41–0·61) 20·4 (14·3–26·0)
Cases/controls 1310/6678 825/3881 249/1376 183/1260
Mean duration of use 4·8 years 1·6 years 6·8 years 13·6 years
First use at age 30 years or older
Relative risk (99% FCI) 0·75 (0·69–0·82) 0·84 (0·76–0·93) 0·63 (0·53–0·74) 0·56 (0·46–0·68) 17·6 (11·6–23·2)
Cases/controls 1740/9337 1131/5583 305/1931 211/1420
Mean duration of use 4·2 years 1·6 years 6·8 years 12·7 years
*Never users include 14 703 cases and 51 908 controls with relative risk of 1·00 (99% FCI 0·96–1·04). All relative risks are stratiﬁ ed by study, age, parity, and hysterectomy. 
Numbers do not always add to the total, because of missing values.
Table 4: Relative risk of ovarian cancer in ever-users of oral contraceptives compared with that in never users, by age at ﬁ rst use and duration of use of 
oral contraceptives
Mid-year of use of oral contraceptives* Test for heterogeneity 
by year of use (p value), 
comparing ever-users
1960s (mostly 
high dose)
1970s (mostly 
medium dose)
1980s (mostly 
low dose)
Current use or use that ceased less than 10 years previously
Relative risk (99% FCI) 0·52 (0·36–0·75) 0·59 (0·51–0·70) 0·55 (0·46–0·65) 0·6
Cases/controls 77/588 474/5164 582/3131
Mean duration of use 7·4 years 5·7 years 5·7 years
Last use 10–19 years previously
Relative risk (99% FCI) 0·70 (0·59–0·83) 0·65 (0·59–0·72) 0·70 (0·53–0·93) 0·6
Cases/controls 387/3027 1077/4609 156/499
Mean duration of use 3·5 years 6·9 years 4·8 years
Last use 20–29 years previously
Relative risk (99% FCI) 0·78 (0·70–0·88) 0·73 (0·67–0·81) Insuﬃ  cient data 0·5
Cases/controls 1037/3530 1152/4567
Mean duration of use 3·7 years 5·4 years
Last use 30 or more years previously
Relative risk (99% FCI) 0·88 (0·77–1·00) 0·79 (0·57–1·11) No data 0·5
Cases/controls 620/2245 75/342
Mean duration of use 2·5 years 2·1 years
*Never users include 14 703 cases and 51 908 controls with relative risk of 1·00 (99% FCI, 0·96–1·04). All relative risks 
are stratiﬁ ed by study, age, parity, and hysterectomy.
Table 5: Relative risk of ovarian cancer in ever-users of oral contraceptives compared with that in 
never users, by calendar year of use and time since last use of oral contraceptives
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contraceptive use in the 1960s and 13% had a mid-year of 
use in the 1980s or later (table 5). Those with a mid-year 
of use in the 1960s had, as expected, ceased use much 
longer ago than those with a mid-year of use in the 1980s 
or later (25 years vs 5 years previously). For a given time 
since last use, however, calendar year of use had little 
eﬀ ect on the relative risk of ovarian cancer (table 5). 
Sensitivity analyses were done classifying women 
according to the calendar year of ﬁ rst use and calendar 
year of last use but, again, no obvious diﬀ erences in 
ovarian cancer risk were found.
The magnitude of the decline in the relative risk of 
ovarian cancer with duration of use did not vary 
signiﬁ cantly according to 13 of the 15 personal 
characteristics examined (ﬁ gure 4). Signiﬁ cant variation 
was seen only with age at diagnosis and menopausal 
status. However, the younger and pre-menopausal 
women had ceased use of oral contraceptives more 
recently than the older and postmenopausal women. 
When analyses were restricted to women whose use 
ceased 10–29 years previously (the only group with 
broadly similar recency of use and also with suﬃ  cient 
information to compare younger versus older women 
and pre-menopausal versus post-menopausal women), 
there was no signiﬁ cant heterogeneity by either age 
(p=0·1) or menopausal status (p=0·4). There was some 
variation in the magnitude of the decline in relative risk 
of ovarian cancer for each year of use of oral 
contraceptives across studies (χ²₂₇=49·1, p=0·006; 
ﬁ gure 1) and by study design (χ²₂=10·4, p=0·006). This 
heterogeneity again reﬂ ects the variation in age and 
thus time since last use of oral contraceptives: cases in 
the prospective compared with the case-control studies 
were older (mean ages of 64 vs 52 years at diagnosis) 
and had ceased use longer ago (means of 24 vs 15 years 
since last use).
Data for histological subtype was available for 
17 099 women with ovarian cancer (74% of the total). 
Among these women the risk of ovarian cancer decreased 
by 21% for each 5 years of use of oral contraceptives 
(ﬁ gure 5), similar to the 20% seen for all women (ﬁ gure 1). 
The reductions in risk per 5 years of oral contraceptive 
use were broadly similar for epithelial and non-epithelial 
tumours. Among the epithelial tumours there was, 
however, heterogeneity across histological types (test for 
heterogeneity, p=0·0007), mainly because oral 
contraceptives seem to have little eﬀ ect on mucinous 
tumours (12% of the total with histology). There was no 
signiﬁ cant heterogeneity in the trends with duration of 
use between the non-mucinous epithelial tumours 
(p=0·5). The ﬁ ndings were similar when the mucinous 
and serous tumours were subdivided into whether they 
were of only borderline malignancy or were fully 
malignant (ﬁ gure 5).
Figure 6 shows, for women in high income countries, 
the estimated cumulative incidence and mortality from 
ovarian cancer for never users of oral contraceptives 
and for those who used them for 5, 10, and 15 years, 
respectively, beginning at age 20 years. The percent 
decline in ovarian cancer rates for every 5 years of use 
was assumed to be 29% in current users and those who 
ceased use in the previous 10 years, 19% in those who 
ceased use 10–19 years previously, and 15% in those 
who ceased use 20 or more years previously. For women 
who never used oral contraceptives an estimated 1·2 in 
every 100 are diagnosed with ovarian cancer and 0·7 in 
every 100 die from the disease before the age of 75 years 
(in the absence of other causes of death). For 10 years 
use of oral contraceptives the estimated cumulative 
incidence was 0·8 per 100 and mortality was 0·5 per 100. 
Cases/controls*
All women                               21345/82112 20·3 (1·8)
Parity                                  
0                                       4374/12445 25·3 (4·7)
1                                       3260/10691 24·8 (4·9)
2                                       6457/23005 18·0 (2·9)
3                                       3846/16017 20·3 (3·9)
≥ 4                                      3179/18995 17·3 (4·7)
Age at ﬁrst birth                      
<20                                     2123/12236 14·9 (6·0)
20–24                                   7169/29817 21·3 (3·0)
25–29                                   4970/18346 14·1 (4·0)
≥ 30                                     2038/7419 22·2 (7·2)
Age at diagnosis                        
<50                                     5902/29961 28·2 (3·4)
≥ 50                                     15443/52151 17·3 (2·1)
Ethnic origin                           
White                                   12782/43499 23·4 (2·6)
Other                                   2005/18878 16·8 (8·6)
Education                               
<13 years                               13301/55542 17·3 (2·4)
≥ 13 years                               5579/20360 21·6 (3·4)
Mother or sister with breast cancer     
Yes                                     1793/4583 19·0 (7·4)
No                                      14261/44678 19·5 (2·1)
Age at menarche                         
<13                                     8008/27013 20·9 (3·1)
≥ 13                                     12770/52931 20·3 (2·4)
Menopausal status                       
Premenopausal                           5899/30933 27·0 (3·2)
Postmenopausal                          13915/45368 16·6 (2·5)
Hormone replacement therapy              
Ever                                    4122/13869 16·5 (4·0)
Never                                   7635/25229 20·3 (4·1)
Hysterectomy                            
Yes                                     2996/10008 12·8 (5·2)
No                                      16818/68580 21·1 (1·9)
Height                                  
<165 cm                                 10931/31928 18·6 (2·7)
≥ 165 cm                                 7586/22646 19·3 (3·0)
Weight                                  
<65 kg                                  9433/27078 19·3 (2·8)
≥ 65 kg                                  8988/27057 18·5 (2·9)
Body-mass index                         
<25 kg/m2                               10869/33251 19·7 (2·5)
≥ 25 kg/m2                               8638/26985 21·2 (3·0)
Alcohol use                             
<50 gm per week                             9925/48497 17·0 (2·5)
≥ 50 gm per week                             3425/11313 21·2 (4·6)
Tobacco use                             
Ever                                    7781/26547 19·1 (2·8)
Never                                   10688/37561 16·9 (2·9)
40% 30% 20% 10% –10% 0%
Users only: percent reduction
in risk† per 5 years of oral
contraceptive use (SE)
Users only: percent reduction
in risk† per 5 years of oral
contraceptive use and 99% CI
Figure 4: Percent reduction in ovarian cancer risk per 5 years oral contraceptive use for various subgroups
Dotted line represents overall result for all women. *Women with missing values are not included for each variable. 
†Stratiﬁ ed by study, age, parity, and hysterectomy. 
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As the reduction in risk is roughly proportional to 
duration of use, this means that for every 5000 
woman-years of oral contraceptive use about two 
ovarian cancers and one death from the disease are 
prevented. (Ovarian cancers arising after age 75 years 
are not included in these or in subsequent calculations, 
nor are deaths from ovarian cancer after age 75 years 
that arose earlier.)
For women with background rates of ovarian cancer 
greater than the average, such as those with a family 
history of breast cancer or who are nulliparous, the 
reduction in absolute risk would be greater still. 
Conversely, for women with lower than average 
background rates the reduction in absolute risk would be 
less. For example, ovarian cancer rates in many 
middle-income and low-income countries are about half 
those in high income countries,59,60 and so about two 
ovarian cancers and one death from the disease would be 
prevented for every 10 000 woman-years of oral 
contraceptive use.
Discussion
This worldwide collaboration has brought together and 
re-analysed data for over 23 000 women with ovarian 
cancer and 87 000 women without ovarian cancer from 
21 countries. The results conﬁ rm that women who use 
oral contraceptives are at a reduced risk of ovarian 
cancer and show that substantial protection continues 
for decades. The reduction in risk is greater the longer 
that women used oral contraceptives and, although the 
relative (but not the absolute) risks are somewhat 
attenuated over time, there is still a signiﬁ cant reduction 
in risk more than 30 years after use has ceased. The 
relative decline in ovarian cancer risk with increasing 
duration of use does not vary substantially by women’s 
ethnicity, education, age at menarche, parity, family 
history of breast cancer, use of hormone replacement 
therapy, body-mass index, height, or their consumption 
of alcohol and tobacco. The incidence of mucinous 
tumours (12% of the total) was little aﬀ ected by oral 
contraceptives, but otherwise the proportional risk 
reduction did not vary much between diﬀ erent 
histological types.
This collaboration includes individual data from 
45 epidemiological studies, most of the eligible studies 
worldwide that have collected information on oral 
contraceptive use and ovarian cancer. Despite extensive 
eﬀ orts to identify studies with unpublished results, we 
cannot guarantee that none has been overlooked or that 
information from continuing prospective studies is up to 
date, since such studies are accumulating data beyond 
the time when they contributed to this collaboration. 
Three published studies48–50 could not contribute their 
data, and only some of the EPIC study centres25,30,36 have 
done so. Nevertheless, these studies would have increased 
the number of cases by only about another 3%, and the 
published results from the studies not included48–50 do not 
All with recorded histology             
Epithelial                              
Clear cell                              
Endometrioid                            
Mucinous                                
    Mucinous borderline                  
Serous                                  
    Serous malignant                     
    Serous borderline                    
Other/mixed                             
Non-epithelial                          
Malignant tumour
not otherwise speciﬁed 
40% 30% 20% 10% –10% 0%
20·5 (1·9)
21·3 (7·3)
27·1 (4·8)
4·0 (4·7)
6·7 (5·8)
–1·5 (7·7)
20·9 (2·7)
22·1 (2·9)
13·0 (6·8)
20·8 (3·9)
19·7 (10·8)
25·8 (7·8)
17099
740
1994
2027
    Mucinous malignant                   1412
615
7131
6263
868
3436
589
1182
Cases Users only: percent reduction
in risk* per 5 years of oral
contraceptive use (SE)
Users only: percent reduction
in risk* per 5 years of oral
contraceptive use and 99% CI
Figure 5: Percent reduction in risk per 5 years use, by ovarian tumour histology
Dotted line represents overall result for all women with recorded histology. Tumour subcategories are shown 
as open squares; the 23 endometroid tumours of borderline malignancy are too few to examine separately. 
*Stratiﬁ ed by study, age, parity, and hysterectomy.
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Duration of oral contraceptive use (incidence to age 75 years) 
Never (1·2%) 
5 years (1·0%) 
10 years (0·8%) 
15 years (0·7%) 
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Duration of oral contraceptive use (mortality to age 75 years) 
Never (0·7%) 
5 years (0·6%) 
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Figure 6: Absolute risk of 
ovarian cancer for women in 
high income countries, by 
duration of use of oral 
contraceptives 
(A) Cumulative incidence of 
ovarian cancer per 100 women. 
(B) Cumulative mortality from 
ovarian cancer per 100 women.
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diﬀ er from those reported. Thus, failure to include all the 
available data has not materially altered the overall 
ﬁ ndings.
Substantial reductions in the oestrogen content of 
oral contraceptives have occurred over the 50 or so years 
that oral contraceptives have been in use. The ovarian 
cancers in this study were diagnosed, on average, 
almost 20 years after the women had last used oral 
contraceptives and, because the speciﬁ c oral contra-
ceptive preparations used are unreliably reported many 
years after use ceases,52 calendar year is used here as an 
indicator of the average oestrogen dose of the 
preparations. Typical oestrogen doses in the 1960s were 
more than double the typical doses in the 1980s and 
later,29,53,54 but for a given pattern of usage there was no 
apparent variation in the relative risk of ovarian cancer 
between women whose oral contraceptive use was 
during the 1960s, 1970s, and 1980s (table 5), sug gesting 
no appreciable diﬀ erential eﬀ ect of prep arations 
typically used over the decades.
One of the main eﬀ ects of oral contraceptives is to 
suppress ovarian activity, so some protection against 
neoplastic change is plausible. This makes it reasonable 
to infer that the associations seen here are chieﬂ y 
causal—ie, that previous oral contraceptive use decreases 
the age-speciﬁ c incidence of ovarian cancer in otherwise 
similar women. The exact mechanism by which oral 
contraceptives cause such a profound and long-lasting 
protection against ovarian cancer is, nevertheless, not 
well understood.
Oral contraceptives were ﬁ rst licensed almost 50 years 
ago. In the 1960s and 1970s most women who had used 
oral contraceptives were younger than 50 and so relatively 
few ovarian cancers would have been prevented (table 6). 
In subsequent decades the estimated proportion of 
cancers prevented increased, in part due to the increasing 
number of ever-users and in part due to the increasing 
age of past users, such that in the 2000s an estimated 
13% of ovarian cancers before age 75 years were being 
prevented in women in high-income countries. In middle-
income and low-income countries oral contra ceptives 
have probably had little eﬀ ect so far on ovarian cancer 
incidence, since use was uncommon until the 1980s.61,62
To illustrate the public-health implications of relative 
risks such as those reported here and the pattern of oral 
contraceptive use around the world, these results suggest 
that of the order of 200 000 incident cases and 
100 000 deaths from ovarian cancer have already been 
prevented over the last 50 years. The number of cancers 
prevented each year is likely to increase substantially in 
the future, with the further ageing of past users of oral 
contraceptives and the increasing numbers of new users, 
especially in middle-income and low-income countries. 
In 2002 an estimated 80 million of a total of 120 million 
oral contraceptives users worldwide were in 
middle-income and low-income countries.61 With this 
number of oral contraceptive users and current ovarian 
cancer incidence rates, the number of ovarian cancers 
prevented would rise over the next few decades to about 
30 000 every year. However, the number prevented is 
likely to be still greater since the prevalence of oral 
contraceptive use in middle-income and low-income 
countries is predicted to increase.62
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